Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
If approved it will bring a second source of MMR vaccine to the US market
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
Subscribe To Our Newsletter & Stay Updated
